Ecstasy use in Australia: Patterns of use and associated harm

Drug and Alcohol Dependence

Volumn 55, Issue 1-2, 1999, Pages 105-115

  Topp, Libby ^a   Hando, Julie ^a   Dillon, Paul ^a   Roche, Ann ^b   Solowij, Nadia ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Ecstasy; Harm; Intervention preferences; Patterns of use; Polydrug use

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE;

ADOLESCENT; ADULT; ARTICLE; AUSTRALIA; FEMALE; HUMAN; INTERVIEW; INTRAVENOUS DRUG ABUSE; MALE; MENTAL DISEASE; MULTIPLE DRUG ABUSE; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; SIDE EFFECT; SUBSTANCE ABUSE;

ADOLESCENT; ADULT; AUSTRALIA; FEMALE; HEALTH STATUS; HUMANS; INTERVIEW, PSYCHOLOGICAL; MALE; MIDDLE AGED; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PATIENT ACCEPTANCE OF HEALTH CARE; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; SUBSTANCE-RELATED DISORDERS;

EID: 0032951913     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0376-8716(99)00002-2     Document Type: Article

References (60)

1. Beck J. The public health implications of MDMA use. Peroutka S.J. Ecstasy: the clinical, pharmacological and neurotoxicological effects of the drug MDMA. 1990;77-103 Kluwer, Boston.
2. Beck J., Rosenbaum M. Pursuit of ecstasy: the MDMA experience. 1994;State University of New York Press, Albany, NY.
3. Biernacki P., Waldorf D. Snowball sampling: Problems, techniques and chain referral sampling. Soc. Methods Res. 10:1981;141-163.
4. Boys A., Lenton S., Norcoss K. Polydrug use at raves by a Western Australian sample. Drug Alcohol Rev. 16:1997;227-234.
5. Cassidy G., Ballard C.G. Psychiatric sequelae of MDMA (ecstasy) and related drugs. Ir. J. Psychol. Med. 11:1994;132-133.
6. Chen K., Kandel D., Davies M. Relationships between frequency and quantity of marijuana use and last year proxy dependence among adolescents and adults in the United States. Drug Alcohol Depend. 46:1997;53-67.
7. Chesher G.B. Designer drugs - the 'whats' and the 'whys'. Med. J. Aust. 153:1990;157-161.
8. Cohen R.S. Subjective reports on the effects of the MDMA ('ecstasy') experience in humans. Prog. Neuropsychopharmacol. Biol. Psychiat. 19:1995;1137-1145.
9. Commonwealth Department of Human Services and Health, 1994. Statistics on drug abuse in Australia, 1994. Australian Government Publishing Service, Canberra.
10. Commonwealth Department of Health and Family Services, 1996. National Drug Household Survey: Survey Report 1995. Australian Government Publishing Service, Canberra.
11. Cook T.M. Cerebral oedema after MDMA ('ecstasy') and unrestricted water intake. Br. Med. J. 313:1996;689.
12. Curran H.V., Travill R.A. Mood and cognitive effects of +3,4-methylenedixoymethamphetamine (MDMA, 'ecstasy'): weekend 'high' followed by mid-week low. Addict. 92:1997;821-831.
13. Dalgarno P.J., Shewan D. Illicit use of ketamine in Scotland. J. Psychoactive. Drugs. 28:1996;191-199.
14. Darke S., Cohen J., Ross J., Hando J., Hall W. Transitions between routes of administration of regular amphetamine users. Addict. 89:1994;1077-1083.
15. Darke S., Ross J., Cohen J. The use of benzodiazepines among regular amphetamine users. Addict. 89:1994;1683-1690.
16. Downing J. The psychological and physiological effects of MDMA on normal volunteers. J. Psychoactive Drugs. 18:1986;335-340.
17. Forsyth A.J.M. Places and patterns of drug use in the Scottish dance scene. Addict. 91:1996;511-521.
18. Fromberg E. XTC: A new soft drug. Tijdschr Alcohol Drugs Andere Psychotrope Stoffen. 16:1990;150-158. (Abstract only).
19. Green S.T., Frischer M., Taylor A., Goldberg D.J., McKeganey N., Bloor M. Increasing ecstasy use among Glasgow drug injectors. Addict. Res. 3:1995;73-76.
20. Griffiths, P., Vingoe, L., Jansen, K., Sherval, J., Lewis, R., Hartnoll, R., Nilson, M. (Eds.), 1997. New trends in synthetic drugs in the European Union: epidemiology and demand reduction responses. EMCDDA Insights Series, Number 1. EMCDDA, Portugal.
21. Hall W. A simplified logic of causal inference. Aust. New Zealand J. Psychiat. 21:1987;507-513.
22. Hall W., Hando J. Route of administration and adverse effects of amphetamine use among young adults in Sydney, Australia. Drug Alcohol Rev. 13:1994;277-284.
23. Hando, J., Hall, W., 1993. Amphetamine use among young adults in Sydney, Australia. NSW Health Department Drug and Alcohol Directorate Research Grant Report Series, B93/2. NSW Health Department, Sydney.
24. Hando J., Topp L., Hall W. Amphetamine-related harms and treatment preferences of regular amphetamine users in Sydney, Australia. Drug Alcohol Depend. 46:1997;105-113.
25. Hando, J., Darke, S., Degenhardt, L., Cormack, S., Rumbold, G., 1998. A comparison of drug use and trends in three Australian States: results from a national trial of the Illicit Drug Reporting System. National Drug and Alcohol Research Centre Monograph No. 36. NDARC, Sydney.
26. Hayner G.N., McKinney H. MDMA: the dark side of ecstasy. J. Psychoactive Drugs. 18:1986;341-347.
27. Henry J.A., Jeffreys K.L., Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ('Ecstasy'). Lancet. 340:1992;384-387.
28. Hosmer D.W., Lemeshow S. Applied logistic regression. 1989;Wiley, New York.
29. Hunt N., Jones K., Shelley H. What happens when ecstasy is injected? (letter). Int. J. Drug Policy. 4:1993;161-162.
30. Institute for the Study of Drug Dependence, 1998. How blue was my ecstasy? Druglink 13 (March/April), 5.
31. Johnston, L.D., O'Malley, P.M., Bachman, J.G., 1997. National survey results on drug use from the Monitoring the Future Study, 1975-1995, vol. 2: College Students and Young Adults. NIH Publication Number 98-4140. National Institute on Drug Abuse, Rockville, Maryland.
32. Kerlinger F.N. Foundations of behavioral research. 3rd ed. 1986;CBS Publishing, Japan.
33. Korf, D.J., Wurth, B., 1995. New drugs in Europe - An overview of trends and monitoring systems in Europe. Pompidou Group, Council of Europe, Strasbourg.
34. Lenton S., Boys A., Norcoss K. Raves, drugs and experience: Drug use by a sample of people who attend raves in Western Australia. Addict. 92:1997;1327-1338.
35. Levine I. Ravers get drugs tested on the spot. The Journal. 23:1994;7.
36. Lilienfeld A.M., Lilienfeld D.E. Foundations of epidemiology. 2nd ed. 1980;Oxford University Press, New York.
37. Matthai S.M., Sills J.A., Davidson D.C., Alexandrou D. Cerebral oedema after ingestion of MDMA ('ecstasy') and unrestricted intake of water. Br. Med. J. 312:1996;13-59.
38. McDermott P. MDMA use in the North West of England. Int. J. Drug Policy. 4:1993;210-221.
39. McGuire P.K., Cope H., Fahy T.A. Diversity of psychopathology associated with use of 3,4-methylenedioxymethamphetamine ('Ecstasy'). Br. J. Psychiat. 165:1994;391-395.
40. Merrill J. Ecstasy and neurodegeneration. Br. Med. J. 313:1996;423.
41. Miller M.A. History and epidemiology of amphetamine abuse in the United States. Klee H. Amphetamine misuse: international perspectives on current trends. 1997;113-134 Harwood Academic, The Netherlands.
42. Moore D. 'Speeding, ecking and tripping': Ethnographic notes from a small world of psychostimulant use. Burrows D., Flaherty B., MacAvoy M. Illicit psychostimulant use in Australia. 1993;71-90 Australian Government Publishing Service, Canberra.
43. Newcombe, R., 1992 A researcher reports from the rave: An inside look at the risks of dance drugs and how to respond. Druglink, Jan/Feb, 14-16.
44. Nichols D.E., Glennon R.A. Medicinal chemistry and structure activity relationships of hallucinogens. Jacobs B.L. Hallucinogens: neurochemical, behavioural and clinical perspectives. 1984;95-142 Raven Press, New York.
45. Norusis, M.J., 1993. SPSS for Windows™: Base System User's Guide, Release 6.0. SPSS, Inc., USA.
46. Ovendon C., Loxley W. Bingeing on psychostimulants in Australia: Do we know what it means (and does it matter)? Addict. Res. 4:1996;33-43.
47. Peroutka S.J. Recreational use of MDMA. Peroutka S.J. Ecstasy: the clinical, pharmacological and neurotoxicological effects of the drug MDMA. 1990;53-62 Kluwer Academic, Boston.
48. Peroutka S.J., Newman J.H., Harris H. Recreational use of 3,4methylenedioxymethamphetamine (MDMA, ecstasy). Neuropsychopharmacology. 1:1988;273-277.
49. Peters A., Davies T., Richardson A. Increasing popularity of injection as the route of administration of amphetamine in Edinburgh. Drug Alcohol Depend. 48:1997;227-237.
50. Pompidou Group, 1997. Group of epidemiological experts in drug problems. Synthesis of the 1995 National Reports. Pompidou Group, Council of Europe, Strasbourg.
51. Release, 1997. Release drugs and dance survey: An insight into the culture. Release, London.
52. Schifano F., Di Furia L., Forza G., Minicuci N., Bricolo R. MDMA ('ecstasy') consumption in the context of polydrug abuse: A report on 150 patients. Drug Alcohol Depend. 51:1998;85-90.
53. Series H., Boeles S., Dorkins E., Peveler R. Psychiatric complications of 'ecstasy' use. J. Psychopharmacol. 8:1994;60-61.
54. Siegel S., Castellan N.J. Nonparametric statistics for the behavioral sciences. 2nd ed. 1988;McGraw-Hill, Singapore.
55. Solowij N. Ecstasy (3,4-methylenedioxymethamphetamine). Curr. Opin. Psychiat. 6:1993;411-415.
56. Solowij N., Hall W., Lee N. Recreational MDMA use in Sydney: A profile of 'ecstasy' users and their experiences with the drug. Br. J. Addict. 87:1992;1161-1172.
57. van Laar M.W., Spruit I.P. Chasing 'ecstasy': use and abuse of amphetamine in the Netherlands. Klee H. Amphetamine misuse: international perspectives and current trends. 1997;247-272 Harwood Academic, The Netherlands.
58. White J., Bochner F., Irvine R. The agony of 'ecstasy': How can we avoid more 'ecstasy'-related deaths? Med. J. Aust. 166:1997;117-118.
59. Williamson S., Gossop M., Powis B., Griffiths P., Fountain J., Strang J. Adverse effects of stimulant drugs in a community sample of drug users. Drug Alcohol Depend. 44:1997;87-94.
60. Winstock A.R. Chronic paranoid psychosis after misuse of MDMA. Br. Med. J. 302:1991;1150-1151.